tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Amarin (AMRN), Amedisys (AMED) and BioMarin Pharmaceutical (BMRN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amarin (AMRNResearch Report), Amedisys (AMEDResearch Report) and BioMarin Pharmaceutical (BMRNResearch Report).

Amarin (AMRN)

In a report released yesterday, Roanna Ruiz from Leerink Partners reiterated a Buy rating on Amarin, with a price target of $10.00. The company’s shares closed last Thursday at $2.78, close to its 52-week low of $2.76.

According to TipRanks.com, Ruiz has 0 stars on 0-5 stars ranking scale with an average return of -27.2% and a 14.3% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amarin with a $9.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Amedisys (AMED)

Leerink Partners analyst Whit Mayo reiterated a Hold rating on Amedisys on April 27. The company’s shares closed last Thursday at $131.89, close to its 52-week low of $122.12.

According to TipRanks.com, Mayo is a 4-star analyst with an average return of 6.9% and a 52.5% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Airsculpt Technologies, Inc., Alignment Healthcare, and Privia Health Group.

Currently, the analyst consensus on Amedisys is a Moderate Buy with an average price target of $189.00.

BioMarin Pharmaceutical (BMRN)

In a report issued on April 27, Joseph Schwartz from Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical, with a price target of $115.00. The company’s shares closed last Thursday at $82.64.

According to TipRanks.com, Schwartz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.3% and a 27.1% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.

Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $114.36, representing a 36.5% upside. In a report issued on April 25, Morgan Stanley also upgraded the stock to Buy with a $113.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed